-ARIUS report new data and program updates on cancer stem cell targeting
TORONTO, April 15 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that it will be presenting new findings and program updates related to its CD44, TROP-2, CD59, and CD9 antibody programs at the American Association for Cancer Research (AACR) Annual Meeting held from April 12-16, 2008 in San Diego, California.
"Our five presentations at AACR shows the tremendous progress we made over the last year with our lead programs. The new findings from our cancer stem cell programs targeting CD44 and CD9 are of particular interest to the scientific community as this is a promising new area of cancer research," said Dr. David Young, President and CEO of ARIUS. "Specifically, we have been able to demonstrate that our CD44 program has the potential for wide therapeutic application in solid tumors, as well as blood cancers. Our cancer stem cell antibody targeting CD9 differentially recognizes AML cancer stem cells compared to normal stem cells. Furthermore, treatment with this antibody can functionally reduce cancer stem cell self-renewal which has very important therapeutic implications."
CD44 Cancer Stem Cell Program
Preclinical development of huARH460-16-2, a humanized antibody to the CD44 cancer stem cell target. Abstract Number 3975. Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM
ARIUS' ARH460-16-2, a functional antibody that targets CD44, has a new
potential cancer indication for pancreatic cancer. The new findings show
anti-tumor effects in an established BxPC3 human pancreatic cancer model
(78.7% tumor growth inhibition at 2 mg/kg compared to control group). This
antibody has broad effects in solid tumors since it have been shown to be
effective in pancreatic, breast, live
|SOURCE ARIUS Research Inc.|
Copyright©2008 PR Newswire.
All rights reserved